SCHEDULE: Tang Capital Boosts Stake in PMV Pharma to 8.9%

Tang Capital Management and affiliated entities have reported an 8.9% beneficial ownership stake in PMV Pharmaceuticals, Inc., holding 4,720,357 shares.

Summary

• Tang Capital Management, LLC, Kevin Tang, Tang Capital Partners, LP, and Tang Capital Partners International, LP, collectively reported beneficial ownership of 4,720,357 shares of PMV Pharmaceuticals, Inc. Common Stock.
• This represents an 8.9% stake in the company, based on 52,990,864 shares outstanding as of August 6, 2025, as reported in PMV Pharmaceuticals' Form 10-Q filed on August 7, 2025.
• All reporting persons, including Tang Capital Management, Kevin Tang, Tang Capital Partners, LP, and Tang Capital Partners International, LP, share both voting and dispositive power over these 4,720,357 shares.
• The reporting persons certified that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of PMV Pharmaceuticals, Inc., other than activities solely in connection with a nomination under Rule 14a-11.

Sentiment

Score: 5

Explanation: The filing is a factual disclosure of beneficial ownership and does not inherently convey positive or negative sentiment regarding the company's performance or outlook. The increased institutional ownership could be seen as a positive signal by some investors.

Positives

• Increased institutional ownership by Tang Capital Management and its affiliates, signaling a vote of confidence in PMV Pharmaceuticals, Inc.'s prospects.
• The reporting group holds significant shared voting and dispositive power over 8.9% of the company's common stock, indicating a substantial, albeit passive, investment.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance from the issuer or the reporting persons regarding PMV Pharmaceuticals, Inc.'s future performance.

Industry Context

This filing indicates a significant passive investment by a specialized capital management firm in a pharmaceutical company. Such investments are common in the biotech and pharma sectors, where long-term growth potential often attracts institutional investors. Tang Capital's stake suggests a belief in PMV Pharmaceuticals' underlying value or future prospects within the industry.

Comparison to Industry Standards

• Not applicable as this filing is an ownership disclosure, not a performance report or operational update that would typically be benchmarked against industry standards or comparable companies.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional investor holding an 8.9% stake may influence investor perception and potentially increase confidence in the company's stock.

Key Dates

Keywords

PMV Pharmaceuticals, Tang Capital Management, Institutional Ownership, Schedule 13G, Common Stock, Equity Stake, Biotech, Pharmaceutical, Investment